Medical News Today -
24 Dec 2013 12:00
Engineered immune cells, called CARTmeso cells, designed to direct antitumor immune responses toward tumors that carry a protein called mesothelin, showed antitumor activity in two patients with advanced cancers that had not responded to prior treatments, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.Chimeric antigen receptor T cells (CAR T cells) are a form of personalized cell therapy that uses immune cells called T cell...
Share this Article